

TABLE OF CONTENTS

Endocrinology I	1
Faculty Panel	3

Gestational Diabetes Mellitus

*By Karen L. Whalen, Pharm.D., BCPS, CDE, FAPhA;
and James R. Taylor, Pharm.D., BCACP, CDE*

Introduction	7
Maternal and Fetal Complications	8
Screening and Diagnosis of GDM	9
Monitoring in GDM	10
Nonpharmacologic Management	10
Drug Therapy for GDM	13
Other Management Strategies	18
Postpartum Management	18
Conclusion	19
References	20
Self-Assessment Questions	23

New Pharmacotherapies for Type 2 Diabetes

*By Charmaine D. Rochester-Eyeguokan, Pharm.D., BCPS, BCACP, CDE;
and Roshni S. Patel, Pharm.D., BCPS*

Introduction	29
Clinical Guideline Updates in Drug Therapy Management	30
A Proposed Classification: The Egregious Eleven	34
Practice Guidelines and Metformin Use	35
Incretin-Based Therapies	36
Updates on CV Safety T2DM	43
Summary	46
New Insulin Products for T2DM	46
Conclusion	49
References	50
Self-Assessment Questions	54

Endocrinology II	59
Faculty Panel	61

Adrenal Insufficiency, Cushing Syndrome, and Hyperaldosteronism

By Dana A. Brown, Pharm.D., BCPS; and Amy M. Henneman, Pharm.D., BCPS, CDE

Introduction	65
Hormone Production and Regulation	65
Hypofunction of the Adrenal Gland	67

Hyperfunction of the Adrenal Gland	72
Monitoring	80
Patient Education	81
References	82
Self-Assessment Questions	84

Hypothyroidism

By Melanie N. Michael, Pharm.D., BCPS

Introduction	89
Physiology of Thyroid Gland	90
Monitoring	96
Patient Counseling	96
Special Populations	96
Conclusion	98
References	98
Self-Assessment Questions	100

Nephrology I	105
Faculty Panel	107

Acute Kidney Injury and Dialysis

By Nancy Hope Goodbar, Pharm.D., BCPS

Introduction	111
ADQI, KDIGO, and NKF KDOQI Guidelines	111
AKI Risk Factors and Etiology	114
Prevention of AKI	116
Management of AKI	120
Renal Replacement Therapy	123
Conclusion	126
References	127
Self-Assessment Questions	129

Nephrolithiasis

By Matthew D. Kostoff, Pharm.D., BCPS, BCACP

Introduction	133
Pathophysiology	133
Risk Factors	134
Acute Treatment	136
Nonpharmacologic Prevention of Stone Recurrence	138
Pharmacologic Prevention of Recurrence Based on Stone Composition	139
Conclusion	142
References	142
Self-Assessment Questions	145

Biostatistics and Study Design

By Daniel R. Malcom, Pharm.D., BCPS, BCCCP; and Tristan Timbrook, Pharm.D., MBA, BCPS

Introduction	149
Fundamentals of Data Analysis	149
Elements of Clinical Trial Design	151

Bias and Confounding	153
Updates in Clinical Trial Design	154
Comparative Effectiveness Research	156
Conclusion	160
References	160
Self-Assessment Questions	162